Eczema (or atopic dermatits) is a chronic, relapsing skin disease affecting up to 30% of children in industrialised countries. The characteristic symptom is the itchy, dry skin lesions which are almost impossible to relieve. Atopic dermatitis is a heterogeneous disorder caused by a complex interplay between genetics and environmental triggers. There is a huge unmet need for new targeted treatments in atopic dermatitis to help patients who are suffering from the disease.
At LEO Pharma we believe that anyone can contribute to our scientific research, and we welcome everyone to participate in drug discovery for better eczema treatments. Everyone can read publicly-available scientific literature and should be able to suggest a new possible target to treat eczema. In order to focus on novel targets, LEO will disclose a list of currently known targets. Only novel suggestions will be evaluated and if found scientifically valid a finder’s fee reward will be paid. LEO Pharma does this in order to increase the chances of discovering new targets and treatment opportunities, and to create a more transparent research interface with external science.
Boosting the open target space with an artificial intelligence event
We are capable of looking for obvious scientific literature that states new discoveries, such as biological pathways and targets, related to eczema. We are working on many such projects, but still feel there could be more out there... By using AI, or machine learning, we hope to be able to pick up evidence and scientific data that lie on the outskirts of the 'obvious'. To do so we need to train an AI tool to identify relevant scientific clues – for this we invite you to participate in a science hackathon aiming to explore new targets in atopic dermatitis.
What: The eczema hackathon is a 2-day research sprint where teams of 3-4 will explore academic literature and map out potential solutions to atopic dermatitis using artificial intelligence. All teams will have access to Iris.ai during the sprint. The winning team will be selected by a panel of judges and awarded a prize of €5,000.
GOALTo identify new targets and pathways for treating atopic dermatitis.
WHEN & WHERE: 9:00am 23rd November 2017 until 6:00pm 24th November 2017 in Copenhagen, Denmark. The venue will be DARE2mansion (http://dare2mansion.com/en/home/), at Vermundsgade 13-15, 2100 København Ø. Participants work on-site throughout the sprint.
WHO WE ARE LOOKING FOR Researchers and students from across research disciplines with a curious mind. Previous experience in the areas of dermatology, immunology or inflammation is not required but might be an advantage.
HOW TO APPLY Go to eczemascithon.eventbrite.com
The event is facilitated by Iris AI and sponsored by LEO Pharma.
Special circumstances: LEO employees may not participate. Healthcare professionals (HCPs) face some restrictions. Tax for reward is covered by the winner.